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BACKGROUND ART
Implantation of an organ (e.g., the heart, a kidney, or a blood vessel) is often followed by a post-transplant rejection response. In an early stage of such a response, inflammation occurs in blood vessels in the transplanted organ, and in a later stage, arteriosclerosis lesions (intimal thickening) are formed. The post-transplant arteriosclerosis event is critical in clinical settings, as it leads to dysfunction of the trans planted organ and a lowered chance of Successful engraft ment. Although a variety of immunosuppressors have been used for management and prevention of Such rejection responses, effects are not necessarily Sufficient and not a few side effects result. Thus, a demand continues to exist for development of a new therapeutic method which takes into consideration the onset mechanism of the pathological con ditions (Transplantation 72 (6 Suppl.): S16-9, 2001). Like wise, similar inflammatory changes are considered to par ticipate in the intimal thickening occurring after transplantation of an auto-or allo-arteriovenous graft.
Recent research in the field of vascular biology has Suggested that inflammation may be a common factor in the pathogenesis of these intractable pathological conditions (N. Engl. J. Med. 340, 115-126, 1999) . Leukocytes have a function of disposal of foreign matter that has invaded the living body from the outside, and when the tissue is dam aged, they come to concentrate at the damaged site, to thereby function to restore the tissue. The inflammation response is recognized as a situation where leukocytes exert their self-defense function excessively to damage the autolo gous tissue. For example, a coronary arteriosclerosis event occurring after heart transplantation is considered to be caused by inflammation evoked as an excessive self-defense response. This type of arteriosclerosis has an onset mecha nism that clearly differs from that of ordinary arteriosclero sis, which involves infiltration of lipids and phagocytosis by macrophages on the lipids to form foamy cells.
An object of the present invention is to provide means for preventing the onset of post-transplant arteriosclerosis or post-transplant intimal thickening by preventing infiltration/ Chemokines are a family of proteins exhibiting chemot actic activity toward leukocytes or lymphocytes. Chemok ines are generally divided into four groups in terms of structure, and those having a molecular structure in which the first and second cysteines are aligned side by side are called CC chemokines.
Monocyte chemoattractant protein-1 (MCP-1), one of Such CC chemokines, has itself been reported as a protein, and its cDNA sequence was elucidated at almost the same time (J. Exp. Med. 169, 1449 Med. 169, -1459 Med. 169, , 1989 J. Exp. Med. 169, 1485 -1490 , 1989 : FEBS lett, 244, 487-493, 1989 .
Receptors that recognize MCP-1 have been identified, and cDNA of each receptor has also been cloned (Proc. Natl. Acad. Sci. USA, 91, 2752 -2756 , 1994 : Biochem. Biophys. Res. Commun. 202, 1156 -1162 , 1994 . Currently, 11 CC chemokine receptors are known, and among them, an MCP-1 receptor is called CCR2.
Rollins et al. engineered amino acid mutants of the MCP-1 protein, and reported that some of them do not exhibit chemotactic activity (J. Bio. Chem. 269, 15918 15924, 1994) . Of such mutants, a mutant named 7ND-MCP 1, in which amino acids 2 to 8 as counted from the N-terminus have been deleted, exhibited no chemotactic ability, although the mutant maintained the ability to bind itself to CCR2, or 7ND-MCP-1 functioned as a dominant negative to form a dimer with wild-type MCP-1, impeding the functions of MCP-1. As has also been known, a deletion occurring at the N-terminus of a chemokine can provide a strong dominant negative inhibitor against interaction with a chemokine receptor, through formation of hetero-dimers with corresponding intrinsic monomers of the chemokine, and that the inhibitor is useful for the treatment of articular rheumatism, inflammatory intestinal disease, multiple scle rosis, chronic pneumonia Such as pulmonary fibrosis, and autoimmune diseases among other diseases (Japanese Kohyo (PCT) Patent Publication No. 11-506005).
Accordingly, the present invention provides a preventive and/or therapeutic agent for post-transplant arteriosclerosis occurring as a rejection response to organ transplantation or for auto-or allo-arteriovenous graft post-transplant intimal thickening, and also provides a preventive and/or therapeu tic method for post-transplant arteriosclerosis occurring as a rejection response to organ transplantation or for auto-or allo-arteriovenous graft post-transplant intimal thickening.
DISCLOSURE OF THE INVENTION
The present inventors intramuscularly injected an expres sion vector (pcDNA3) containing a 7ND-MCP-1 gene to a model animal (mouse) at the thigh, and confirmed that 7ND-MCP-1 protein produced in the vector-plasmid-intro duced muscle cells significantly Suppressed the development of arteriosclerosis (intimal thickening) in an implanted heart. The present invention also provides use of an MCP-1 function inhibitor in the manufacture of a preventive and/or therapeutic agent for post-transplant arteriosclerosis occur ring as a rejection response to organ transplantation or for auto-or allo-arteriovenous graft post-transplant intimal thickening.
The present invention also provides a preventive and/or therapeutic method for post-transplant arteriosclerosis occurring as a rejection response to organ transplantation or for auto-or allo-arteriovenous graft post-transplant intimal thickening, characterized by administering, to a subject in For example, an anti-MCP-1 antibody may be obtained through the method described in J. Immunology, 147,2229 Immunology, 147, 2233 Immunology, 147, , 1991 , and an MCP-1 antagonist and an MCP-1 dominant negative are known from, for example, Japanese Kohyo (PCT) Patent Publication No. 11-506005.
In the present invention, transfer of a gene coding for an MCP-1 function inhibitor is preferred over administration of a protein serving as an MCP-1 function inhibitor to the living body, in view that the gene can remain in the living body (blood) for a prolonged period of time.
In the present invention, use of an MCP-1 antagonist oran MCP-1 dominant negative, interalia, use of 7ND-MCP-1, is preferred. Furthermore, genes coding for an MCP-1 antago nist or an MCP-1 dominant negative are preferred, with a gene coding for 7ND-MCP-1 being more preferred. As a gene coding for 7ND-MCP-1, DNA having a nucleotide sequence of SEQ ID NO: 1 is employed. This DNA can be engineered through a genetic engineering technique known per se. Briefly, the DNA can be created through PCR employing synthetic primers and the nucleotide sequence of DNA coding for a wild-type MCP-1 of SEQ ID NO: 2. No particular limitations are imposed on the expression vector to be used for inducing expression of the gene in the living body, so long as the vector attains its assigned functions. Examples of useful vectors include plasmid vec tors such as pcDNA3, pEF-BOS, and pXT1, and retrovirus vectors such as adenovirus and Sendai virus. When an expression vector is constructed, a promoter or an enhancer may be used, and in this case, no particular limitation is imposed on the promoter or the enhancer, so long as it functions in the host (living body). Examples of the pro moter include, but are not limited to, SV40 promoter, CMV promoter, HSV-TK, SRC, and RSV.
In order to cause a gene to be expressed in the host (living body), use of a liposome may be another choice. In this case, the gene may be present inside the liposome, inside the lipid bilayer membrane that constitutes the liposome, or outside the membrane. A diversity of liposome compositions have been known to have the ability to express a gene in the host (living body).
In order to confirm that the 7ND-MCP-1 gene in fact produces 7ND-MCP-1 protein, ELISA assay may be per formed to detect the protein in serum.
Indications of the drugs of the present invention include post-transplant arteriosclerosis (intimal thickening) occur ring as a rejection response to organ transplantation and auto-or allo-arteriovenous graft post-transplant intimal thickening.
The MCP-1 function inhibitor, which is an active ingre dient of the preventive and/or therapeutic agent for post transplant arteriosclerosis or auto-or allo-arteriovenous graft post-transplant intimal thickening, is administered to the living body orally or parenterally. When the MCP-1 function inhibitor is a protein, parenteral administration is preferred. Examples of the parenteral administration include injection, and no particular limitations are imposed on the injection route. For example, intra-arterial, intravenous, intramuscular, transdermal, or Subcutaneous injection may be performed at any site other than the implanted organ or the graft. When the MCP-1 function inhibitor is adminis tered through injection, the product form may be a liquid for injection, which can be produced through a known drug production technique. In the manufacture of injection prod ucts, known additives may be used, including, for example, an isotonicity agent, a buffer, a preservative, a vehicle, and a Soothing agent. The dosage may be determined in consid eration of the patient's condition, age, sex, body weight, etc. The dose may be 0.1 to 1,000 mg in the case of a protein, or 0.01 to 100 mg in the case of a gene, and in either case, the dose may be administered once every 2 to 4 weeks.
EXAMPLES
The present invention will next be described in more detail by way of examples, which should not be construed as limiting the invention thereto.
(1) Construction and Expression of 7ND-MCP-1 A vector plasmid coding for 7ND-MCP-1 was constructed through recombinant PCR using, as a template, pcDNA3 vector plasmid encoding MCP-1. The presence of all muta tions was confirmed by the DNA sequence analysis per formed in both directions. The resultant PCR product coding
